Appointment dossier — Fallopian Tube Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Fallopian Tube Cancer
Compounds named in the cited literature for Fallopian Tube Cancer, labeled by the strongest evidence found:
- bevacizumab — Phase III trial
- niraparib — Phase III trial
- nivolumab — Phase III trial
- olaparib — Phase III trial
- relacorilant — Phase III trial
- rucaparib — Phase III trial
- trabectedin — Phase III trial
- carboplatin — Phase II trial
- cediranib — Phase II trial
- cyclophosphamide — Phase II trial
- docetaxel — Phase II trial
- docetaxel plus carboplatin — Phase II trial
- gemcitabine — Phase II trial
- iniparib — Phase II trial
- levonorgestrel — Phase II trial
- pegylated liposomal doxorubicin — Phase II trial
- topotecan — Phase II trial
- topotecan and bevacizumab — Phase II trial
- navicixizumab — Phase I trial
- oxaliplatin — Phase I trial
- paclitaxel — Phase I trial
- paclitaxel poliglumex — Phase I trial
- veliparib — Phase I trial
- chemotherapy — Meta-analysis
- nab-paclitaxel — Tested in people
- nemvaleukin alfa — Tested in people
- paclitaxel and carboplatin — Tested in people
- pembrolizumab — Tested in people
- peritoneal washing cytology — Meta-analysis
- aflibercept — Named in the literature
- atezolizumab — Named in the literature
- bevacizumab-combined single-agent chemotherapy — Named in the literature
- bilateral salpingo-oophorectomy — Named in the literature
- bortezomib — Named in the literature
- BRCA1/2 mutation — Named in the literature
- Cantrixil — Named in the literature
- carbon ion radiotherapy — Named in the literature
- cisplatin — Named in the literature
- combined oral contraceptives — Named in the literature
- etoposide — Named in the literature
Open recruiting trials (18)
- NCT06915025 · Phase 3 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer (United States)
- NCT05281471 · Phase 3 — Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (United States)
- NCT04657068 · Phase 1 / Phase 2 — A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (United States)
- NCT03983226 · Phase 2 — Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) (China)
- NCT06906341 · Phase 2 — Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (United States)
- NCT07586826 · Phase 2 — Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors (China)
- NCT05867251 · Phase 1 / Phase 2 — Study of AVZO-021 in Patients With Advanced Solid Tumors (United States)
- NCT05080556 · Phase 2 — Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer (United Kingdom)
- NCT05200260 · Phase 2 — Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer (China)
- NCT04811703 · Phase 1 — Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer (France)
- NCT07402915 · Phase 1 — Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Georgia)
- NCT05092373 · Phase 1 — Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (United States)
- NCT06469281 · Phase 1 — A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (United States)
- NCT06024109 — Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy (Germany)
- NCT06730347 · Phase 2 — A Study of Lorigerlimab in Participants With Advanced Solid Tumors (United States)
- NCT05737303 · Phase 3 — Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer (China)
- NCT06412510 · Phase 1 / Phase 2 — Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT (United States)
- NCT05128825 · Phase 2 — A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (United States)
Most-relevant first: trials that name Fallopian Tube Cancer, then broader trials you may still qualify for. 117 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- I've read that bevacizumab has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that niraparib has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that nivolumab has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT06915025), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?